These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20653680)

  • 1. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
    Paré L; Paez D; Salazar J; Del Rio E; Tizzano E; Marcuello E; Baiget M
    Br J Clin Pharmacol; 2010 Aug; 70(2):268-72. PubMed ID: 20653680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
    Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
    Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
    Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
    Savva-Bordalo J; Ramalho-Carvalho J; Pinheiro M; Costa VL; Rodrigues A; Dias PC; Veiga I; Machado M; Teixeira MR; Henrique R; Jerónimo C
    BMC Cancer; 2010 Sep; 10():470. PubMed ID: 20809970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
    Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.
    Cerić T; Obralić N; Kapur-Pojskić L; Macić D; Beslija S; Pasić A; Cerić S
    Bosn J Basic Med Sci; 2010 May; 10(2):133-9. PubMed ID: 20507294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
    Uzunkoy A; Dilmec F; Ozgonul A; van Kuilenburg AB; Akkafa F
    Anticancer Res; 2007; 27(6B):3899-902. PubMed ID: 18225548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
    Zhang H; Li YM; Zhang H; Jin X
    Med Oncol; 2007; 24(2):251-8. PubMed ID: 17848752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
    Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
    Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
    Kleibl Z; Fidlerova J; Kleiblova P; Kormunda S; Bilek M; Bouskova K; Sevcik J; Novotny J
    Neoplasma; 2009; 56(4):303-16. PubMed ID: 19473056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent intragenic rearrangements of DPYD in colorectal tumours.
    van Kuilenburg AB; Etienne-Grimaldi MC; Mahamat A; Meijer J; Laurent-Puig P; Olschwang S; Gaub MP; Hennekam RC; Benchimol D; Houry S; Letoublon C; Gilly FN; Pezet D; Andre T; Faucheron JL; Abderrahim-Ferkoune A; Vijzelaar R; Pradere B; Milano G
    Pharmacogenomics J; 2015 Jun; 15(3):211-8. PubMed ID: 25348620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
    Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
    Salgueiro N; Veiga I; Fragoso M; Sousa O; Costa N; Pellon ML; Sanches E; dos Santos JG; Teixeira MR; Castedo S
    Genet Med; 2004; 6(2):102-7. PubMed ID: 15017333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
    Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
    Gross E; Meul C; Raab S; Propping C; Avril S; Aubele M; Gkazepis A; Schuster T; Grebenchtchikov N; Schmitt M; Kiechle M; Meijer J; Vijzelaar R; Meindl A; van Kuilenburg AB
    Br J Cancer; 2013 Oct; 109(9):2347-55. PubMed ID: 24104963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.